Overview of the drug development for Guillain-Barre syndrome

Guillain-Barre syndrome (GBS) is an autoimmune disorder in which the immune system mistakenly attacks healthy nerve cells, thus leading to weakness in the muscles, numbness, and tingling. It can eventually cause paralysis. The immune system destroys the myelin sheath surrounding the axons of peripheral nerves, which carry nerve signals. Nerve cells start losing the ability to transmit signals efficiently when myelin sheath is injured. The actual cause of GBS is unknown, but it usually occurs a few days after a patient had symptoms of a respiratory or gastrointestinal viral infection. Zika virus infection is also linked to GBS. According to CDC’s report in August 2016, GBS is associated with Zika and in many countries where the population is affected with Zika, have reported an increase in GBS patient population. Furthermore, according to CDC, every year approximately 3,000-6,000 people in the US develop GBS. With the increase in the age, the incidences of GBS also increases. As a result, with the increasing incidences of the disease, the need for the drug development for Guillain-Barre syndrome is expected to increase considerably in the upcoming years.

According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for Guillain-Barre syndrome. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of Guillain-Barre syndrome. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Akari Therapeutics
• Alexion
• Complement Pharma
• Hansa Medical
• Vitality Biopharma

Therapeutic assessment of the drug development for Guillain-Barre syndrome by route of administration

• Intravenous
• Oral
• Subcutaneous

The intravenous route of administration (ROA) involves the application of the drug directly into the veins, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development for Guillain-Barre syndrome by therapy

• Monotherapy
• Combination therapy

According to this pipeline analysis report, most of the molecules that are currently in the drug development for Guillain-Barre syndrome are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug molecules in the various development stages for Guillain-Barre syndrome?
• What are the companies that are currently involved in the development of drug molecules for Guillain-Barre syndrome?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.